Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
10.40
+0.09 (0.87%)
At close: Jan 31, 2025, 4:00 PM
10.25
-0.15 (-1.44%)
After-hours: Jan 31, 2025, 7:50 PM EST
Vir Biotechnology Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Vir Biotechnology stock have an average target of 34.83, with a low estimate of 14 and a high estimate of 110. The average target predicts an increase of 234.90% from the current stock price of 10.40.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for VIR stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 3 |
| Hold | 3 | 3 | 3 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $110 | Strong Buy | Reiterates | $110 | +957.69% | Jan 31, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $18 → $20 | Buy | Maintains | $18 → $20 | +92.31% | Jan 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $110 | Strong Buy | Reiterates | $110 | +957.69% | Jan 10, 2025 |
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $10 → $20 | Hold → Buy | Upgrades | $10 → $20 | +92.31% | Jan 9, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $10 → $14 | Hold | Maintains | $10 → $14 | +34.62% | Jan 9, 2025 |
Financial Forecast
Revenue This Year
69.34M
from 86.18M
Decreased by -19.54%
Revenue Next Year
30.66M
from 69.34M
Decreased by -55.79%
EPS This Year
-3.97
from -4.59
EPS Next Year
-3.62
from -3.97
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 106.7M | 111.5M | 95.1M | |||
| Avg | 69.3M | 30.7M | 38.3M | |||
| Low | 60.6M | n/a | 4.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 23.8% | 60.8% | 210.3% | |||
| Avg | -19.5% | -55.8% | 24.9% | |||
| Low | -29.7% | - | -84.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.89 | -2.73 | -2.56 | |||
| Avg | -3.97 | -3.62 | -3.51 | |||
| Low | -3.94 | -5.17 | -5.62 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.